In particular, it is important to closely monitor the innovations made by the Biogen group with the obtaining of new patents or the advancement of clinical trial phases on drugs under development.
Although Biogen has experienced strong growth in recent years, for the moment it prefers to follow a policy of reinvesting its profits in its activities, particularly in R&D. For this reason, no dividend has been paid to its shareholders for the moment. However, this does not mean that this will not be the case in the years to come.